Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia; and AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. Affimed N.V. has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; and Roivant Sciences Ltd., as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.
Earnings for Affimed N.V. (AFMD)
Earnings in 2023 (TTM): $-105,935,000
According to Affimed N.V.'s latest financial reports the company's current earnings (TTM) are $-105,935,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Affimed N.V.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-105,935,000 | $-105,938,000 |
| 2022 | $-86,002,000 | $-86,004,000 |
| 2021 | $-57,521,000 | $-57,523,000 |
| 2020 | $-41,365,000 | $-41,366,000 |
| 2019 | $-32,361,000 | $-32,365,000 |
| 2018 | $-19,476,000 | $-19,477,000 |
| 2017 | $-30,243,000 | $-30,223,000 |
| 2016 | $-32,274,000 | $-32,216,000 |
| 2015 | $-20,239,000 | $-20,239,000 |
| 2014 | $-425,000 | $-259,000 |
| 2013 | $-26,100,000 | $-26,099,000 |
| 2012 | $-14,323,000 | $-14,314,000 |